LUNGevity Foundation shared a post on LinkedIn:
” ‘Anyone involved in cancer testing has seen firsthand that timely and consistent biomarker testing still isn’t standard everywhere. What’s different about this study is that it puts real numbers behind what’s been intuitively understood for years – showing, in data, the gaps and barriers that patients are still facing,’ says Martin.
LUNGevity’s Nikki Martin will be presenting Results from an Online Survey: Understanding Use of Biomarker Testing at Diagnosis in NSCLC (Poster No. 194) at the ASCP 2025 Annual Meeting on Tuesday, November 18, from 12:00–12:45 pm ET.
More posts featuring LUNGevity Foundation.